No, You Cannot Reduce Apixaban from 5 mg Twice Daily to 2.5 mg Once Daily
The FDA-approved dosing for apixaban is either 5 mg twice daily (standard dose) or 2.5 mg twice daily (reduced dose) for patients requiring indefinite anticoagulation—there is no approved 2.5 mg once daily regimen for this indication 1.
Critical Dosing Error in Your Question
Your question contains a fundamental error: you're asking about reducing from "5 mg OD" (once daily) to "2.5 mg OD" (once daily). Apixaban is never dosed once daily for chronic anticoagulation in atrial fibrillation or VTE treatment beyond the initial phase. The only exception is the 2.5 mg twice daily regimen used specifically for extended VTE prophylaxis after completing at least 6 months of full-dose treatment 1.
Correct Dosing Regimens
For Atrial Fibrillation (Stroke Prevention):
- Standard dose: 5 mg twice daily
- Reduced dose: 2.5 mg twice daily ONLY if patient meets ≥2 of the following criteria 2, 1:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
For VTE Treatment:
- Acute treatment: 10 mg twice daily for 7 days, then 5 mg twice daily 1
- Extended treatment (after ≥6 months): 2.5 mg twice daily for reduction of recurrence risk 1
Why You Cannot Arbitrarily Reduce to 2.5 mg Twice Daily
Inappropriate dose reduction is associated with significantly worse outcomes. A large real-world study of 280,709 patients with atrial fibrillation found that 61% of patients receiving reduced-dose apixaban did not meet criteria for dose reduction. These patients on inappropriate low-dose apixaban had substantially higher mortality (adjusted HR: 1.77; 95% CI: 1.66-1.88) compared to those on appropriate full-dose therapy 3.
When 2.5 mg Twice Daily IS Appropriate
1. Extended VTE Treatment Context:
After completing at least 6 months of therapeutic anticoagulation for VTE, you may switch to 2.5 mg twice daily for long-term recurrence prevention. Recent meta-analysis data support this approach, showing that reduced-dose DOACs (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) compared to standard dose resulted in 4:
- Similar recurrent VTE rates (1.66% vs 1.78%; RR 0.94)
- Lower major bleeding (1.16% vs 1.96%; RR 0.62)
- Lower clinically relevant non-major bleeding (5.16% vs 7.00%; RR 0.75)
This benefit extends to high-risk populations including cancer patients 5 and those with recurrent VTE 4.
2. Drug Interactions:
When patients on 5 mg twice daily require combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir), reduce to 2.5 mg twice daily 1.
Critical Pitfalls to Avoid
- Never use once-daily dosing for chronic anticoagulation (except in specific post-surgical prophylaxis scenarios not relevant here)
- Never arbitrarily reduce dose without meeting FDA criteria—this increases mortality risk
- Never assume "lower is safer" in elderly or frail patients without meeting specific criteria—underdosing kills more than it protects
- In hemodialysis patients, even 2.5 mg once daily may result in undetectable drug levels in 30% of patients, suggesting inadequate anticoagulation 6
The Bottom Line Algorithm
If patient is on 5 mg twice daily for atrial fibrillation:
- Does patient meet ≥2 dose reduction criteria (age ≥80, weight ≤60 kg, creatinine ≥1.5)?
- YES → Consider 2.5 mg twice daily
- NO → Continue 5 mg twice daily
If patient completed ≥6 months VTE treatment:
- Is goal extended prophylaxis rather than active treatment?
- YES → Switch to 2.5 mg twice daily 1
- NO → Continue 5 mg twice daily
Never use 2.5 mg once daily for chronic anticoagulation.